Alkaline phosphatase (AP) is a gate-keeper of innate immune system responses by detoxifying inflammation triggering moieties released from endogenous and external sources. We examined whether AP's broad mechanism of action constitutes a safe therapeutic, either as single agent or combined with methotrexate (MTX), for chronic inflammatory disorders, for example, rheumatoid arthritis (RA). A rat model for RA was used with repeated intra-articular methylated bovine serum albumin (mBSA) injections in 1 knee ("arthritic" knee), with the contralateral knee serving as internal control. AP (200 mg, subcut) was administered before mBSA injections (prophylactic setting) or after arthritis induction (therapeutic setting) or combined with MTX (0.3 mg/kg or 1 mg/kg; intraperitoneally). As end point of treatment outcome, macrophage infiltration in knees, liver, and spleen was assessed by immunohistochemistry (ED1 and ED2 expression), immunofluoresence (macrophage marker folate receptor-b [FRb]), and [
Abbreviations: ACPA = anti-citrullinated protein antibody; AP = recombinant human placental alkaline phosphatase = hRESCAP Ò (human rescue alkaline phosphatase); DAS = disease activity score; DMARD = disease modifying anti-rheumatic drug; EULAR = European league against rheumatism; FR = folate receptor; i.a = intra-articular; %ID/g = percentage of the injected dose per gram; i.p = intraperitoneally; mBSA = methylated bovine serum albumin; MTX = methotrexate; PEG = polyethylene glycol; PET-CT = positron emission tomography-computed tomography; RA = rheumatoid arthritis; s.c = subcutaneously
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Background
Inflammation triggering moieties (ITMs) such as adenine nucleotides (AMP, ADP, ATP) when released extracellularly, provoke a pro-inflammatory response. Alkaline phosphatase (AP) functions as a gate-keeper of innate immune system responses by detoxifying, that is, dephosphorylating ITMs.
INTRODUCTION
Rheumatoid arthritis (RA) is an auto-immune disease with hallmarks of synovial and systemic inflammation which, when left untreated, leads to progressive bone and joint destruction. [1] [2] [3] Current treatment options for RA include chemical disease modifying anti-rheumatic drugs (cDMARDs) with methotrexate (MTX) and glucocorticoids as predominant initial treatments. 4, 5 MTX has an established place in RA treatment based on its low cost, safety profile, efficacy, and long-standing clinical experience. 6, 7 Still, a considerable fraction (30%À40%) of RA patients is faced with MTX intolerance or inefficacy early on in the treatment or loss of efficacy during chronic treatment. [8] [9] [10] [11] At this stage, treatment with biological DMARDs (bDMARDs) is indicated, 1 but these come with higher costs and are also prone to development of resistance. 10, 12 Therefore, identification of novel modalities that could reinforce longer-lasting efficacy of MTX, or have alternative mechanisms of action, deserve continued interest.
Alkaline phosphatase (AP), a glycosylphosphatidylinositol-anchored protein, is a member of the family of ectophosphatase proteins. [13] [14] [15] [16] [17] At least 4 different enzyme isoforms of AP are differentially expressed in various tissues (eg, liver, intestine, placenta, bone) and immune cells (eg, macrophages) from where AP may be released in soluble form by glycosylphosphatidylinositol-specific phospholipase D. 16, 18 As ectophosphatases act extracellularly by dephosphorylating inflammation triggering moieties (ITMs), AP is thought to have a gate-keeper function in the innate immune system by detoxifying well-known ITMs from external and internal sources such as lipopolysaccharides, CpG oligodeoxynucleotides, and nucleotide phosphates (adenosine tri-, di-, and mono-phosphates [ATP, ADP, and AMP], respectively). [19] [20] [21] [22] [23] [24] [25] Whereas increased concentrations of extracellular nucleotide phosphates exert pro-inflammatory signals, 26, 27 their ectophosphatase-mediated conversion to adenosine conveys a well-recognized anti-inflammatory effect via interactions with adenosine receptors. 28 This mechanism of action is reminiscent of the dominant anti-arthritic mechanism of action of MTX, [8] [9] [10] 29 which involves the non-lytic extracellular release of adenosine and extrusion of adenine nucleotides (AMP, ADP, ATP) that are converted to adenosine by the action of ectophosphatases CD39 and CD73 on immune-competent cells. 30 Recent evidence indicates that downregulation of CD39 on regulatory T cells during MTX treatment inhibits local generation of adenosine, thereby conferring MTX resistance in RA. 31 Under conditions of attenuated CD39 and CD73 function, AP may compensate for their function. AP therapeutic interventions have been studied in preclinical and clinical models of local and systemic inflammatory diseases. In fact, in animal models, exogenous ectophosphatase interventions by AP resulted in near-complete inhibition of systemic tumor necrosis factor-alpha (TNFa), interleukin (IL6), and IL8 response after a systemic inflammatory insult with lipopolysaccharide. 23, 32 In humans, AP administration prevented the induction of these pro-inflammatory cytokines or chemokines peri-and postsurgically in patients undergoing open heart surgery. 33, 34 In the RA setting, AP intervention is relatively unexplored. As a preliminary account, a safety assessment (phase 1/2a) study of multiple injections with bovine intestinal AP (twice daily, 2000 U, sc, for 3 days) in 6 RA patients (treatmentresistant, severe RA, including anti-TNF failures) with 3 months' follow-up showed no safety events, 1 sustained and 1 transient clinical response with temporary improvement of disease activity score (DAS) response (A Hammond, unpublished data). Bovine AP, however, is rather short-lived (T 1/2 max: 2 hours), which hampers proper repeated treatments.
In this study, the potential anti-arthritic activity of AP was examined in an established rat model of RA. 35 This model is characterized by extensive synovial macrophage infiltration upon arthritis induction, which is also a hallmark of RA disease in humans. 36 Moreover, upon therapeutic intervention, reduction of synovial macrophage infiltration indicates efficacy of therapy in human RA. 37, 38 The purpose of this study was to assess the impact of longer-lived recombinant human placenta AP as stand-alone treatment and in combination with MTX on synovial macrophage infiltration in arthritic rats. Additionally, to assess potential systemic anti-inflammatory effects, the impact of AP on macrophage infiltration in liver and spleen in arthritic rats was investigated. 
MATERIALS AND METHODS
Animals. Groups of 3À6 Wistar rats (male, 150À200 g, Charles River International Inc, Sulzfeld, Germany) were provided with standard food and water (ad libitum) under conditions described previously. 38 All animal experiments were performed according to the criteria and guidelines of European Community Council Directive 2010/63/EU for laboratory animal care and the Dutch Law on animal experimentation. The experimental protocol was approved by the local committee on animal experimentation of the VU University (DEC PET13-07).
Arthritic induction and therapeutic interventions. All (except healthy control) rats were immunized and arthritis was induced via 1£ or 4£ intra-articular (i.a.) methylated bovine serum albumin (mBSA) injections, 4 or 5 days apart in the arthritic (right) knee, with the contralateral (left, nonarthritic) knee serving as control as described before. 35 For therapeutic interventions, AP (hRESCAP Ò , TNO, Zeist, The Netherlands) was administered subcutaneously (s.c.) at a dose of 700 U/kg (%200 mg), and MTX (Pharmacy VU University Medical Center, Amsterdam, The Netherlands) was administered intra-peritoneally (i.p.) at 2 dosages: 0.3 mg/kg (low dose) and 1.0 mg/kg (high dose). Rats were divided into 8 groups, as depicted in Fig 1, based on different treatments and treatment schedules. In a prophylactic setting, 2 rats received AP twice before i.a. arthritis induction and 4 rats received AP twice before i.a. injections and 4£ phosphate buffered saline (PBS) between i.a. injections. In the treatment groups, arthritic rats were administered AP twice or 4 times after arthritis induction, either as stand-alone therapy or in combination with lowor high-dose MTX. Control rats received 500 mL of PBS (i.p.). Healthy rats did not receive arthritic induction or any treatment. At the end of each study, all rats were sacrificed and tissues excised for further analysis.
Alkaline phosphatase activity. An enzymatic assay was used to determine plasma concentrations of AP before and 0À4 hours after administration of a dose of 700 U/kg AP to healthy rats and arthritic rats. At time points 0, 15, 60, 120, and 240 minutes after AP administration, a blood sample was drawn from the tail vein of the rats and transferred to a 1-mL Eppendorf microtube containing heparin (454081, Greiner bio-one, Charlotte, N.C.) as anticoagulant. As a control, blood was drawn at the same time points from arthritic rats that were injected a t = 0 with 500-mL PBS. Eppendorf tubes were centrifuged at 3000 £ g for 5 minutes at 4˚C, after which the plasma was collected and stored at ¡80˚C until use.
The enzymatic assay for AP was based on the conversion of the substrate paranitrophenol-phosphate (PNP; 104105, Sigma-Aldrich, Zwijndrecht, The Netherlands) to paranitrophenol, which is measured spectrophotometrically at 405 nm at 25˚C. To a 3-mL reaction cuvette was added 2.9-mL substrate solution (containing final concentrations of 25-mM glycine, 10 mM MgCl 2, 3-mM PNP, adjusted to pH 9.6 with NaOH). The reaction was started by adding 30 mL of plasma sample, 1:1 diluted in enzyme diluent buffer (25-mM glycine, 1-mM MgCl 2 , 0.1-mM ZnCl 2 , 10% (v/v) glycerol, adjusted to pH 9.6 with NaOH). In parallel, a reference cuvette was assayed without substrate. The reaction was followed online for 5 minutes at 25˚C with continuous monitoring increase of absorbance at 405 nm using a spectrophotometer (10037-434, VWR, Radnor, Pa.). From the linear phase of A405 increments, AP activity in plasma samples (in U/L) was calculated from a standard curve with serial dilutions of a human recombinant placenta AP stock solution. One unit of activity was defined as the amount of enzyme decomposing 1 mmol of PNP/min at 25˚C and pH 9.6.
Histopathology and immunohistochemistry. The arthritic and contralateral knees from all rats were dissected in toto and fixed for 7 days at 4˚C in 10% freshly made paraformaldehyde in PBS with 2% sucrose (pH = 7.3) before decalcification in osteosoft (101728, Merck, Darmstadt, Germany) for~2.5 weeks at RT. Thereafter, knees were embedded in paraffin. Sections of 5 mm were cut through the center of the joint in longitudinal direction and stained with hematoxylin and eosin (HE) to assess the degree of inflammation in synovial tissue. Liver and spleen sections from all rats were dissected and fixed in 4% paraformaldehyde for 24 hours before embedding in paraffin. Sections of 5 mm were cut and stained initially with HE and then for macrophages. Staining for macrophages with ED1 (homologous to human CD68) and ED2 (homologous to human CD163, a marker for M2 anti-inflammatory macrophages) or isotype control antibody was performed as described in detail previously. 38 Images were captured using a Leica 4000B microscope and Leica digital camera DC500 (Microsystems B.V., Rijswijk, The Netherlands).
FRb immunofluorescence and microscopy. Liver and spleen tissues collected at the end of the study were snapfrozen in liquid nitrogen and stored at ¡80˚C. Tissues were embedded in appropriate media (OCT; SKU4583, Tissue-Tek, Amsterdam, The Netherlands), cut using a cryotome cryostat (¡20˚C) (Leica, Amsterdam, The Netherlands) and placed on Superfrost (4951PLUS4, ThermoFisher, The Netherlands) glass slides for IF staining. Sections of 8 mm were cut and stained with HE. Immunostaining of FRb was performed with a mouse anti-rat FRb antibody 42 or isotype control antibody. Specifically, liver and spleen tissue sections were first brought to room temperature (RT) for 30 minutes, fixed in acetone (439126, Sigma-Aldrich, Zwijndrecht, The Netherlands)
Timeline of arthritis induction in rats and interventions with AP, MTX, and AP-MTX combinations. On day 7 and day 14, the first and second immunization (Im1 and Im2) with mBSA was performed; on day 19, the DTH test, followed by 4 (unless otherwise indicated) i.a. injections, as depicted. Interventions were made with AP (700 U/kg), MTX (0.3 mg/kg or 1.0 mg/kg), or AP-MTX combinations, as depicted. To 2 group of rats prophylactic administration of AP was given, that is, twice before arthritis induction. All other groups received therapeutic administration of AP or MTX after arthritis induction. As a control, untreated arthritic rats received injections with PBS. PET-CT (#) was performed before (day 22) and after (day 40) AP therapy. At the end of the study (day 40), rats were sacrificed and TD was performed. Healthy rats did not receive any arthritic induction and treatment, and were sacrificed on day 26. (Black arrows = i.a. injections; light gray arrows = AP; and dark gray arrows = MTX.) AP, alkaline phosphatase; MTX, methotrexate; DTH, delayed type hypersensitivity; mBSA, methylated bovine serum albumin; i.a., intra-articular; PBS, phosphate buffered saline; PET-CT, positron emission tomography-computed tomography; TD, tissue distribution.
for 10 minutes (¡20˚C) and air-dried for 10 minutes (RT). A DAKO pen was used to mark sections (S2002, DAKO, Santa Clara, Calif.), which subsequently were washed 3£ with PBS on a shaker. Hereafter, sections were incubated with 100% fetal bovine serum (FBS) for 30 minutes (RT) to block nonspecific binding and washed again in PBS (3£ for 5 minutes). Next, sections were incubated with anti-rat FRb (1:50) in 10% FBS/PBS or with 10% FBS/PBS for 24 hours at 4˚C. After washing (3£ for 5 minutes in PBS on a shaker), sections were incubated for 1 hour at RT with secondary antibody goat-anti-mouse Alexa 488 (1:500) (R37120; ThermoFisher, Landsmeer, The Netherlands) in 10% FBS/PBS, air-dried, and mounted (2 mL of MOWIOL mounting medium 81381, Merck, Zwijndrecht, The Netherlands). The 2-D IF slides were imaged with a Zeiss Axiovert 200M Marianas (Breda, The Netherlands) inverted microscope (40£ oilimmersion lens). The microscope, camera, and data processing were controlled by SlideBook software (SlideBook version 6, Intelligent Imaging Innovations, Denver, Colo.) as described previously. 43 Quantification of macrophages in knee sections, liver, and spleen. All stained slides were blinded and counted by 2 independent observers for ED1 + and ED2 + synovial macrophages. To this end, the knee section was divided into 4 quadrants (Q1ÀQ4), each representing the joint capsule with synovial tissue lining on either side of the proximal and distal side of the bone. Under the microscope (Leica) at 400£ magnification, 2À3 areas in each quadrant were counted for macrophages in lining and sublining (1À10 layers) of the synovium. The average number of macrophages per area from all 4 quadrants were combined and used as total number of ED1 or ED2 macrophages ( § standard deviation [SD] ).
Stained slides of liver and spleen sections of arthritic rats and AP-treated arthritic rats were blinded and counted by 2 independent observers for FRb, ED1 + and ED2 + synovial macrophages. For quantification, representative areas of liver and spleen sections were divided into 4 regions, each representing a central pulp and vein, respectively. The FRb + , ED1 + and ED2 + macrophages were counted at 400£ magnification as described above. The average number of macrophages per area from all 4 regions were combined and used as total number of FRb, ED1, or ED2 macrophages. As a control liver and spleen sections of healthy rats were analyzed. ]fluoro-PEG-folate was synthesized as previously described, 41 with a radiochemical purity of >96.5% and a mean specific activity of 27.6 § 3.5 GBq/mmol. Untreated and 4£ AP-treated arthritic rats were anesthetized using inhalation anesthetics (isoflurane 2%À2.5% and oxygen 0.45 volume %). The tail vein was cannulated with a polyurethane 3-French cannula (0.7 mm £ 19 mm, BD Angiocath, Breda, The Netherlands). During PET-CT (Mediso nanoPET-CT, Budapest, Hungary), rats were place in an integrated heating bed (~35˚C) while monitoring respiratory function. A CT scan was performed for 5 minutes, followed by tracer administration (10.7 § 1.8 MBq) at the start of a dynamic PET scan of 60 minutes. PET data were normalized, and corrected for scatter, randoms, attenuation, decay, and dead time. List mode PET data were rebinned in 19 consecutive frames (4 £ 5, 4 £ 10, 2 £ 30, 3 £ 60, 2 £ 300, 3 £ 600, and 1 £ 900 seconds), which were reconstructed using an iterative 3-D Poisson ordered-subsets expectation-maximization algorithm with 4 iterations and 6 subsets. Resulting images had a matrix size of 225 £ 225 £ 236 voxels, each with a dimension of 0.40 £ 0.40 £ 0.46 mm 3 . Images were analyzed using AMIDE software (A Medical Image Data Examiner, version 0.9.2, Department of Radiology, Stanford University, Stanford, CA, USA) 44 and were expressed as standardized uptake values, that is, mean region of interest (ROI) radioactivity concentration normalized to injected dose and body weight. CT and PET images were superimposed for drawing the ROIs. Using the last frame, fixed-size ellipsoidal-shaped ROIs (dimensions: 7 £ 4 £ 8 mm 3 ) were manually drawn over the area of both arthritic and contralateral knees. Time activity curves were extracted by projecting ROI onto the dynamic image sequence.
Ex vivo tissue distribution studies. At the end of the treatment period, arthritic rats receiving 4£ AP, 4£ AP/low-dose MTX, 4£ AP/high-dose MTX treatment, and untreated rats were administered with [
18 F]fluoro-PEG-folate tracer (10.7 § 1.8 MBq). Sixty minutes after tracer administration, rats were sacrificed. Lowand high-dose MTX-treated arthritic rats were sacrificed without tracer administration. Next, knees, blood, and various internal organs were excised, rinsed, dipped dry, weighed, and the amount of radioactivity determined using an LKB 1282 Compugamma CS gamma counter (LKB, Wallac, Turku, Finland). Tracer uptake in the various tissues was expressed as percentage of injected dose per gram tissue (%ID/g). 38 Statistical analysis. Statistical analyses were performed using SPSS version 15 for Windows (SPSS Inc, Chicago, Ill.). The Wilcoxon signed-rank (exact) test was used to determine differences in paired observations, such as macrophage infiltration in arthritic vs contralateral knees. Mann-Whitney (exact) tests were performed to analyze differences in macrophage infiltration in groups, for example, arthritic vs PBS-treated knees. A P-value <0.05 was considered statistically significant. All results are presented as mean § SD.
RESULTS
Arthritis induction and AP-MTX therapeutic interventions. Arthritis induction in rats was associated with measurable macroscopic thickening (swelling) of the arthritic knee compared with the contralateral control knee (data not shown). Therapeutic interventions with AP, MTX, or their combination, as depicted in Fig 1, were well tolerated and not associated with any adverse effects. No significant changes in the body weight were observed. Accurate assessments of macroscopic decrease of swelling in the arthritic knee joints during treatment were not feasible because of interference of repeated i.a. injections. For this reason, microscopic assessments of knee joints were performed (see later discussion).
Alkaline phosphatase pharmacokinetics. Plasma AP pharmacokinetics were assessed in healthy rats and arthritic rats following intraperitoneal injection of 700 U/ kg AP, which is the same amount used in therapeutic interventions depicted in Fig 1. As a control, plasma AP levels were determined in arthritic rats injected with PBS. Baseline plasma levels of AP were slightly but significantly (P < 0.05) higher in healthy rats (0.27 § 0.01 U/ mL) than in arthritic rats (0.21 § 0.02 U/mL; Fig 2) . After AP administration, plasma AP levels increased over 1 hour to reach a maximum that was 1.5-and 1.7-times higher than baseline levels in healthy and arthritic rats, respectively. It should be noted that increased plasma AP levels in healthy rats were retained for at least 4 hours, whereas in arthritic rats, AP plasma levels steadily returned to baseline levels within this time frame. AP levels in PBS-injected arthritic rats were unchanged over the 4-hour sampling period (Fig 2) .
Effects of AP, MTX, and AP-MTX combination therapy on synovial macrophage infiltration. The ability of AP, MTX, and AP-MTX to suppress synovial macrophage infiltration in knee joints of arthritic rats was used as a primary end point for therapy efficacy assessment. To this end, macrophage numbers were quantified in arthritic knee section vs the contralateral knee section by immunohistochemical assessment of the abundance of both total ED1 + and ED2 + macrophages, the latter being a representative marker for anti-inflammatory macrophages. 45 Representative (Fig 3, A) and ED2 + (Fig 3, B) macrophages in the arthritic knees. This was confirmed by 4-fold (P < 0.01) and 8-fold (P < 0.01) lower levels of ED1 + (Fig 3, C) and ED2 + (Fig 3, D) macrophages in arthritic knees of AP-pretreated arthritic rats compared with untreated rats. These reduced levels were comparable with macrophage counts in contralateral knees. Two AP administrations (followed by 4£ PBS) resulted in a significant 2-fold (P < 0.01) and 3-fold (P < 0.01) reduction in synovial ED1 + (Fig 4, A) and ED2 + (Fig 4, B) macrophage infiltration in arthritic knees. In a therapeutic setting, 4£ AP administration further reduced these macrophage counts in arthritic knees by another~8-fold (P < 0.001) (Fig 4) . Next, effects of AP treatment in combination with MTX on synovial macrophage infiltration were examined using either a dose of 1 mg/kg MTX that was previously shown to be effective 38 or a lower dose of 0.3 mg/kg MTX. AP-MTX combinations were well tolerated and resulted in numerically increased reductions of ED1 + synovial macrophages when compared with stand-alone MTX or AP treatment (Fig 4, A) . The differences did not reach statistical significance for individual groups, but when MTX 0.3 and 1.0 mg/kg MTX groups were combined, ED1 + Fig 2. AP plasma pharmacokinetics in healthy and arthritic rats. Healthy and arthritic rats were administered 700 U/kg AP, and (as control) arthritic rats received an injection with PBS. Blood samples were drawn at baseline and at 15, 60, 120, and 240 minutes after an AP injection, after which plasma samples were processed for AP enzymatic activity assays. Results are presented as mean § SD for 2 rats per group and assays performed in duplicate. AP, alkaline phosphatase; PBS, phosphate buffered saline; SD, standard deviation. macrophages were significantly reduced (P < 0.01) in AP-MTX combinations over MTX stand-alone treatment (Fig 4, A) . Also for ED2 + macrophages, numerical reductions of MTX-AP combinations were observed, but these did not reach statistical significance over stand-alone MTX or AP treatment as these treatments were already very effective (Fig 4, B) . (Fig 5) . The coronal PET-CT image showed higher tracer uptake in the untreated arthritic rats than in the 4£ APtreated rats (Fig 5, A) . [
18 F]fluoro-PEG-folate standardized uptake value in the synovial region of interest (white ellipsoid) was 1.5-fold higher in the arthritic knee of the untreated rat (Fig 5, B) compared with the arthritic knee of 4£ AP-treated rat (Fig 5, C) .
Ex vivo tissue distribution studies. Following PET studies, tissues were collected from untreated (only PBS), APtreated, AP + 0.3 mg/kg MTX-treated, and AP + 1.0 mg/kg MTX-treated arthritic rats, and tracer uptake was quantified as %ID/g. In excised knee sections of untreated (only PBS) arthritic rats, tracer uptake was 1.5-fold higher (P < 0.05) in the arthritic knee than in the contralateral knee (0.408 § 0.01 vs 0.283 § 0.01) (Fig 5, D) . After AP treatment, [ 18 F]fluoro-PEG-folate uptake in the arthritic knee was 20% lower (0.342 § 0.04%ID/g). AP combined with either 0.3 or 1.0 mg/kg MTX further reduced tracer uptake by 1.6-to 1.8-fold (P < 0.05) in arthritic knees compared with PBS controls (Fig 5, D) . These levels were comparable with those in contralateral knees of untreated rats (results not shown).
The impact of AP treatment, either stand-alone or combined with MTX, on [ 18 F]fluoro-PEG-folate tracer uptake in other tissues is depicted in Table I . In all treatment groups, [18F]fluoro-PEG-folate was rapidly cleared from plasma (Table I) . Notably, AP and AP-MTX treatments also showed reduced [ 18 F]fluoro-PEG-folate uptake in high macrophage resident organs, that is, lung, heart, liver, and spleen (Table I) . Consistent with high expression of FRa in kidney and intestine, 46 tracer uptake was high in these organs, but not affected by AP and AP-MTX treatments (Table I) .
Systemic anti-inflammatory effects of AP in arthritic rats.
To examine whether the reduced tracer uptake in liver and spleen of AP-treated arthritic rats was associated with reduced macrophage infiltration in those organs, ED1 and ED2 immunohistochemistry was performed on liver (Fig 6) and spleen (Fig 7) section of salinetreated vs AP-treated arthritic rats, with liver and spleen tissue of healthy rats as a reference. Representative images of ED1 + and ED2 + macrophages in liver and spleen sections are shown in Fig 6, AÀH and Fig 7, AÀH, respectively. Quantifications of ED1 + and ED2 + macrophages in liver (Fig 6, I and J) and spleen (Fig 7, I and J) showed significantly higher (~4-to 5-fold, P < 0.001) levels in the organs of arthritic rats compared with those of healthy rats, pointing to a systemic inflammatory component. Following AP treatment, a marked and significant decrease (~50%, P < 0.01) of both ED1 + and ED2 + infiltrating macrophages was observed in liver of arthritic rats (Fig 6,  I and J) . Similarly, in spleen of arthritic rats, AP treatment also resulted in a significant reduction (~30%, P < 0.01) of both ED1 + and ED2 + infiltrating macrophages (Fig 7, I and J) . Antibody control-stained liver and spleen sections were clearly negative for both ED1 + and ED2 + macrophages (Figs 6 and 7, A, B, E, and F).
Effect of AP on FRb + macrophages in liver and spleen of arthritic rats. To verify whether reduced [ 18 F]fluoro-PEG-folate tracer uptake in liver and spleen of APtreated arthritic rats (Table I) was associated with reduced numbers of FRb + macrophages, cryosections of liver and spleen tissues were examined for FRb expression by IF. Representative images and quantitative results are shown in Fig 8, AÀE (for liver) and Fig 8, EÀJ (for spleen) . In liver and spleen of arthritic rats, the number of FRb + macrophages was significantly higher (4-to 6-fold, P < 0.001) than in corresponding organs of healthy rats. After AP therapeutic interventions, the number of FRb + was markedly reduced in both liver (~60% reduction, P < 0.001) and spleen (~50% reduction, P < 0.001) of arthritic rats. Antibody control-stained liver and spleen sections were negative (Fig 8, A, B and F, G) .
DISCUSSION
The main finding of this study is that interventions with AP elicit prophylactic anti-arthritic activity in rats by suppressing arthritis induction after i.a. antigen injection. Moreover, in a therapeutic setting, that is, after arthritis induction, AP intervention also conveyed local anti-arthritic effects represented by a marked reduction of synovial macrophage infiltration as well as systemic anti-arthritic effects as represented by lowered macrophage infiltration in liver and spleen of arthritic rats. Lastly, AP activity is preserved in treatment combinations with MTX.
Multiple administrations of AP spaced over 4 days were well tolerated by arthritic rats. Based on our Table I Representative immunohistochemical (HE) images of ED1 + and ED2 + macrophages in liver sections of healthy rats, saline-treated (control) arthritic rats, and AP-treated arthritic rats. A, B, Isotype control-stained liver sections of saline-treated and AP-treated rats, respectively. C, D, ED1 + macrophages in liver of saline-treated and AP-treated rats, respectively. E, F, Isotype control-stained liver sections of saline-treated and AP-treated rats, respectively. G, H, ED2 + macrophages in liver of saline-treated and AP-treated rats, respectively. I, J, Quantifications of ED1 + and ED2 + macrophages in liver of healthy, saline-treated, and AP-treated rats. Values depict mean number of macrophages counted in predefined areas of the liver. Error bars indicate SD. **P < 0.01; ***P < 0.001. HE, hematoxylin and eosin; AP, alkaline phosphatase; SD, standard deviation.
previously reported data, a once every 4 days' schedule was used, taking into account the biological half-life of AP in rats of %3 days. 47 Monitoring AP plasma pharmacokinetics after a single intraperitoneal dose of 700 U/kg AP in healthy and arthritic rats showed peak plasma levels after 1 hour, which were about 50%À70% above baseline (Fig 2) . In healthy rats, this increased AP level in plasma remained stable for 4 hours, whereas in arthritic rats AP plasma levels dropped to basal levels within 4 hours. These results confirm previous data on consumption of available AP during condition of oxidative stress due to endotoxin release 32 such as in RA, and organ injury as with cardiovascular events and cardiothoracic surgery. 33, 48, 49 During its action, AP is consumed, supposedly by conjugating to its ITM substrates, and eliminated by Kupffer cells. 32 AP after reacting to ITMs and removal from circulation by Kupffer cells does not return to plasma. 32 Studies by Tuin et al 50 showed that under these circumstances de novo synthesis of AP was initiated.
Therapy with an AP harboring a long plasma residence time will then only be consumed when needed, specifically during exacerbations when other ectophosphatases cannot cope with the ITM insult. Alternatively, AP can be administrated as an injectable during exacerbations to assist combating the surge in ITM, rather than using or consuming AP reserves in the body. Consistently, this mode of action may also be involved in the prophylactic activity of AP in dampening antigen-induced arthritis in rats. Acting as an anti-inflammatory protein, the net effect of AP will be to prevent pro-inflammatory cytokines like TNFa and IL6 to be produced by activated immune cells, thereby preventing downstream effects in the inflammatory cascade. The same mode of action of AP may contribute to the therapeutic activity of AP in rats with established arthritis and reflected by reduced macrophage infiltration in the synovium. Removal of ITMs will suppress production of pro-inflammatory cytokines and reduce chemotaxis to attract monocyte and/or + and ED2 + macrophages in spleen sections of healthy rats, saline-treated (control) arthritic rats, and AP-treated arthritic rats. A, B, Isotype control-stained spleen sections of saline-treated and AP-treated rats, respectively. C, D, ED1 + macrophages in the spleen of saline-treated and AP-treated rats, respectively. E, F, Isotype control-stained spleen sections of saline-treated and AP-treated rats, respectively. G, H, ED2 + macrophages in the spleen of saline-treated and AP-treated rats, respectively. I, J, Quantifications of ED1 + and ED2 + macrophages in spleen of healthy, saline-treated, and APtreated rats. Values depict mean number of macrophages counted in predefined areas of the spleen. Error bars indicate SD. ***P < 0.001. HE, hematoxylin and eosin; AP, alkaline phosphatase; SD, standard deviation. macrophage cells. 51 In addition, systemic and local inflammations are associated with increased vascular permeability and leukocyte extravasation. [52] [53] [54] [55] In this regard, AP has also been thought to improve barrier dysfunction by restoring tight junctions between polarized cells, thereby attenuating cell migration. 21 Studies addressing the impact of bDMARD treatment in human RA did not influence monocyte migration into RA synovium but rather impacted macrophage efflux from the synovium. 56, 57 Given these observations, the effect of AP on the dynamics of monocyte influx and macrophage retention in RA synovium warrants further investigations.
Inflamed RA synovium is characterized by the presence of differentiated or polarized macrophages covering a spectrum of pro-inflammatory (M1) and antiinflammatory (M2) macrophages. [57] [58] [59] Both AP and MTX interventions reduced both ED1 + -and ED2 + macrophage infiltrations in synovial tissue. ED2 represents the rat homologue of human CD163, which has been assigned a marker for M2-type macrophages. 45, 60 This classification may not be that rigid as M2-marcrophages in an arthritic synovial microenvironment with anti-citrullinated protein antibody (ACPA) antibodies and complex IgG autoantibodies were found to produce pro-inflammatory cytokines. 61, 62 AP, just like MTX, 63 may thus impact synovial infiltration of polarized inflammatory macrophages.
As many cDMARD and bDMARD treatments in RA are combined with MTX, 1 in the present study, the efficacy of AP and MTX combinations in arthritic rats were + macrophages in liver and spleen sections of healthy rats, saline-treated (control) arthritic rats, and AP-treated arthritic rats. A, B, Isotype control-stained liver sections of saline-treated and AP-treated rats, respectively. C, D, FRb + macrophages in the liver of saline-treated and AP-treated rats, respectively. E, Quantifications of FRb + macrophages in liver of healthy rats, saline-treated, and AP-treated rats. F, G, Isotype control-stained spleen sections of saline-treated and AP-treated rats, respectively. H, I, FRb + macrophages in the spleen of saline-treated and AP-treated rats, respectively. J, Quantifications of FRb + macrophages in spleen of healthy rats, saline-treated, and AP-treated rats. Values depict mean number of macrophages counted in predefined areas of the liver. Error bars indicate SD. ***P < 0.001. AP, alkaline phosphatase; FR, folate receptor; SD, standard deviation. studied specifically. AP-MTX combinations were well tolerated and slightly more effective in terms of reducing synovial macrophage infiltration. Immunohistochemistry data (Fig 4) provided some indication of a synergistic effect of AP + MTX although both treatments already showed clear efficacy as single agents. These results indicate that it may be possible to reduce MTX dosages even further in optimization of the AP-MTX combination. Mechanistically, it is conceivable that AP can complement the anti-arthritic effects of MTX by supporting the extracellular conversion of pro-inflammatory AMP, ADP, and ATP into anti-inflammatory adenosine by the action of the ectophosphatases CD39 and CD73 on immunecompetent cells. 30, 31 Under normal conditions, CD39 and CD73, acting locally as high affinity but low capacity ectophophatases, have sufficient governing power over low-pathogenicity increases of extracellularly exposed nucleotides. However, under pathologic conditions, for example, during exacerbations in chronic inflammatory disorders, they become stoichiometrically occupied. Systemically, the responding immune system has a backup system in place with the broad-acting ectophosphatase AP. In contrast to its reduced efficacy, AP has a high capacity, providing a safety net in pathologic conditions or postoperative inflammatory effects 33, 48, 49 where highaffinity CD39 and CD73 cannot sufficiently cope with surges of nucleotides.
[
18 F]fluoro-PEG-folate PET 38, 41 and ex vivo tissue distribution studies proved to be of added value to monitor the effects of AP and MTX treatment in arthritic rats (Fig 5) . It should be taken into account that imaging and ex vivo tissue distribution studies include the whole knee joint instead of only synovial tissue as in immunohistochemical studies. This may explain why differences in untreated and treated arthritis are less pronounced when comparing tracer uptake in knee sections and macrophage counts in synovial tissue. [ 18 F]fluoro-PEG-folate ex vivo tissue distribution studies indicate that AP and AP-MTX combinations had systemic effects beyond reducing synovial macrophage infiltration. Systemic inflammation, indicated by increased macrophage infiltration in liver and spleen, has been reported in rats with adjuvantinduced arthritis. 64 In the present study, liver and spleen of arthritic rats also showed increased infiltration of macrophages, which were markedly decreased upon AP treatment (Fig 6À8) . This reduction of macrophages included FRb + macrophages that constituted a marker for activated macrophages.
39, 40 The lowered number of FRb + macrophages after AP treatment may account for reduced tracer uptake in liver and spleen in the ex vivo tissue distribution studies (Table I) . These results point to systemic anti-inflammatory effects elicited by AP, which underscores systemic activity of AP observed in other animal models of inflammatory diseases. 32 Altogether, conceptually, ectophosphatase intervention by AP may fulfill a novel, unique, and unmet niche in RA treatment by combining different, yet synergistic mode of actions with MTX and other cDMARDs and bDMARDs. AP as anti-inflammatory protein could be positioned as a promising new RA treatment either as stand-alone therapy or in combination with MTX. Being an endogenous protein, AP lacks resistance formation or tolerization effects. AP's potential is further supported by a wide "safety window of use" and proven safety of recombinant human AP in human volunteer safety studies when AP was administered once every 24 hours for 3 consecutive days. 65 Moreover, also in pregnant women, plasma AP levels increase up to 30-fold over baseline levels without any signs of toxicity. 66 Notwithstanding these facts, before application in an RA setting, safety of repeated AP dosing will have to be confirmed. Anticipating therapeutic applications of AP in RA treatment, macrophage PET imaging may be an attractive noninvasive modality to monitor therapy response. 38, 67 In conclusion, AP, both as prophylactic and as therapeutic intervention, demonstrated favorable articular and systemic anti-arthritic efficacy in a rat model of arthritis. These studies warrant further preclinical and clinical evaluation of AP as a putative novel therapeutic entity for arthritis.
